Research & Development



  而白登山,無疑會成為戰場上的一個核心……   銀屏惡狠狠地威脅蒙查。人人摸   “嗤——”人人看   十幾年過去了,確實如趙破奴所說,在這里繁衍生息的羌人通過自己的雙手,為自己掙得了富足的生活。   曹襄也沒有發怒,而是指著猶自被謝長川拿在手里的文牒道︰“你以為我想渾水?沒的選擇罷了。”超碰在线   霍去病瞅著雲瑯道︰“你的正事是好好地改善一下兄弟們的伙食,不是拉開尸體找蠟丸。不要跟這個老家伙往近里走,任何跟他親近的人最後都沒有什麼好下場,至少有一半,是被他親手干掉的。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo